Application of lorcaserin hydrochloride in preparation of medicine for suppressing opioid addiction and withdrawal reaction

Abstract

The invention relates to an application of Lorcaserin hydrochloride in preparation of a medicine for inhibiting opioid addiction and withdrawal syndrome. The Lorcaserin hydrochloride is approved to be a weight-reducing aid by the America Food and Drug Administration (FDA) in 2012. The Lorcaserin hydrochloride is a 5-hydroxytryptamine 5-HT2C receptor stimulant with high selectivity. The latest research of the invention finds that the Lorcaserin hydrochloride (0.5-1.0mg.kg<-1>) greatly reduces the naloxone-urged horizontal motion distance and speed of a morphine dependent mice and the withdrawal syndrome of the mice. It is found in the invention for the first time that the Lorcaserin hydrochloride can be applied clinically for rescuing and treating addiction and withdrawal syndrome generated by morphine and other opiates.

Description

technical field [0001] The invention belongs to the field of drugs for treating the addiction and withdrawal behavior of morphine and other opioid substances, and specifically relates to a new application of a clinical medicine for treating the addiction and withdrawal behavior of morphine and other opioid substances. Background technique [0002] Hazards and Mechanisms of Opioid Addiction [0003] The abuse and addiction of the opioid morphine and its chemically synthesized derivative heroin have become medical and social problems of global concern. Opioids and drug abuse have become a growing social problem in our country and many other countries, especially Southwest Asia, Central Asia, Southeastern Europe and North America (World Drug Report 2013, United Nations Office on Drugs and Crime). Drug users in China mainly abuse heroin and other opioids. By the end of 2012, there were 2.098 million registered drug users nationwide, of which 1.272 million were opioid abusers, a...

Images